Last reviewed · How we verify
ABT-414
At a glance
| Generic name | ABT-414 |
|---|---|
| Also known as | Depatuxizumab, Mafodotin, Depatuxizumab Mafodotin |
| Sponsor | AbbVie |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (PHASE3)
- UNITE Study: Understanding New Interventions With GBM ThErapy (PHASE3)
- Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma (PHASE1, PHASE2)
- Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (PHASE2)
- Expanded Access to ABT-414
- A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor (PHASE1)
- Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme (PHASE1)
- A Study of ABT-414 in Subjects With Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-414 CI brief — competitive landscape report
- ABT-414 updates RSS · CI watch RSS
- AbbVie portfolio CI